CTS™ KnockOut™ SR XenoFree 培养基
Invitrogen17万+抗体限时买二赠一，靶点广，灵活用！
CTS™ KnockOut™ SR XenoFree 培养基
引用和文献 (5)
Gibco™

CTS™ KnockOut™ SR XenoFree 培养基

Gibco CTS KnockOut SR XenoFree 培养基（配制为完全培养基时）能够在仅含人源性蛋白或人重组蛋白的细胞培养基中支持人胚胎干细胞 (hESC) 和人诱导性多能干细胞了解更多信息
Have Questions?
更改视图buttonViewtableView
货号数量
12618013500 mL
12618012100 mL
货号 12618013
价格（CNY)
11,883.00
Each
添加至购物车
数量:
500 mL
价格（CNY)
11,883.00
Each
添加至购物车
Gibco CTS KnockOut SR XenoFree 培养基（配制为完全培养基时）能够在仅含人源性蛋白或人重组蛋白的细胞培养基中支持人胚胎干细胞 (hESC) 和人诱导性多能干细胞 (hiPSC) 的生长和扩增，有助于 hESC 和 hiPSC 研究从实验台向临床过渡。

在从研究应用向临床应用过渡时，CTS 产品系列能够减少试剂验证方面的负担。

CTS KnockOut SR XenoFree 培养基不含牛或其他非人动物源性组分。除多能干细胞培养物扩增和维持培养外，CTS KnockOut SR XenoFree 培养基还可用于 hESC⁄hiPSC 冻存、衍生化和分化研究。

Gibco CTS 产品质量较高，并附有相应的证明文件，如分析证书、原产地证书，还可获取药物主文件授权书（如适用）。
用于研究或生产基于细胞、基因或者组织的产品。注意：不可直接作用于人类或动物给药。
规格
细胞类型胚胎干细胞 (ESC)、诱导型多能干细胞 (iPSC)
适用于（应用）细胞和基因治疗研究，开发和生产
产品规格瓶装
生产质量ISO 13485、21 CFR 820
产品类型干细胞培养基
数量500 mL
运输条件干冰
分类无异种成分
形式液体
血清水平无血清
无菌无菌过滤
Unit SizeEach
内容与储存
在 -5 至 -20°C 下避光储存

常见问题解答 (FAQ)

我应如何鉴定人胚胎干（ES）细胞？

人体ES细胞一般可通过以下方法进行鉴定：经典型的形态（它们以致密的细胞团形式生长 生长为紧密聚集的小型细胞团，细胞小并具有高核质比）；表面标志物的表达；干细胞特异性基因表达的RT-PCR检测（如Oct3/4，Sox2和Nanog）；碱性磷酸酶染色和端粒酶活性检测。最为常用的人ES细胞特异性表面标志物包括发育阶段特异性的胚胎抗原SSEA-3和SSEA-4。其它的ES细胞特异性的其它表面抗原还包括TRA-1-60和TRA-1-81。（Science 282:1145 (1998)）。

人胚胎干（ES）细胞是怎么获得的？

人胚胎干细胞源自人类囊胚内细胞团, 是通过使用兔抗血清检测BeWO细胞（人滋养层细胞系）抗血清的通过免疫外科法手段来进行分离的（Science 282:1145 (1998)）。

何为胚胎干（ES）细胞？

胚胎干（ES）细胞是源自早期哺乳动物胚胎的细胞，能够在体外进行无限的未分化增殖，同时保留分化为各类成体组织（包括生殖细胞）的潜能。ES细胞的多能性通常在体外通过以下方法来证明：将ES细胞诱导分化为类拟胚体，并以谱系特异性的标志物检测三个体胚层（内胚层，中胚层和外胚层）中分化细胞的谱系特异性标志物分化情况，或将这些细胞注射到免疫缺陷型小鼠中，以检测畸胎瘤中产生的细胞类型。

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Do you offer a medical device–grade of CTS KnockOut SR XenoFree Medium?

Yes, we do offer a Class II medical device–labeled CTS KnockOut SR XenoFree Medium in the USA and Canada only. Please contact us at custommedia@thermofisher.com to discuss if a medical device grade is required for your application.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

View all CTS™ KnockOut™ SR XenoFree 培养基 FAQs

引用和文献 (5)

引用和文献
Abstract
CD133-enriched Xeno-Free human embryonic-derived neural stem cells expand rapidly in culture and do not form teratomas in immunodeficient mice.
Authors:Haus DL, Nguyen HX, Gold EM, Kamei N, Perez H, Moore HD, Anderson AJ, Cummings BJ
Journal:
PubMed ID:25082219
'Common methods for the generation of human embryonic-derived neural stem cells (hNSCs) result in cells with potentially compromised safety profiles due to maintenance of cells in conditions containing non-human proteins (e.g. in bovine serum or on mouse fibroblast feeders). Additionally, sufficient expansion of resulting hNSCs for scaling out or up ... More
An ECM-based culture system for the generation and maintenance of xeno-free human iPS cells.
Authors:Kim HT, Lee KI, Kim DW, Hwang DY
Journal:Biomaterials
PubMed ID:23153417
'Pluripotent stem cells (PSCs) including induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) have emerged as a promising source for treating incurable diseases. Problems that urgently need to be resolved before the clinical application include avoiding potential xenopathogenic transmission and immune rejection that may be caused by the ... More
Concise Review: Manufacturing of Pancreatic Endoderm Cells for Clinical Trials in Type 1 Diabetes.
Authors:Schulz TC,
Journal:
PubMed ID:26062982
'The cellular component of ViaCyte''s VC-01 combination product for type 1 diabetes, pancreatic endoderm cells (PEC-01) derived from CyT49 human embryonic stem cells, matures after transplantation and functions to regulate blood glucose in rodent models. The aims in manufacturing PEC-01 at scale are to generate a consistent and robust transplantable ... More
Generation of human-induced pluripotent stem cells by a nonintegrating RNA Sendai virus vector in feeder-free or xeno-free conditions.
Authors:Macarthur CC, Fontes A, Ravinder N, Kuninger D, Kaur J, Bailey M, Taliana A, Vemuri MC, Lieu PT,
Journal:Stem Cells Int
PubMed ID:22550511
The generation of induced pluripotent stem cells (iPSCs) from somatic cells has enabled the possibility of providing unprecedented access to patient-specific iPSC cells for drug screening, disease modeling, and cell therapy applications. However, a major obstacle to the use of iPSC for therapeutic applications is the potential of genomic modifications ... More
cGMP production of patient-specific iPSCs and photoreceptor precursor cells to treat retinal degenerative blindness.
Authors:Wiley LA, Burnight ER, DeLuca AP, Anfinson KR, Cranston CM, Kaalberg EE, Penticoff JA, Affatigato LM, Mullins RF, Stone EM, Tucker BA,
Journal:Sci Rep
PubMed ID:27471043
'Immunologically-matched, induced pluripotent stem cell (iPSC)-derived photoreceptor precursor cells have the potential to restore vision to patients with retinal degenerative diseases like retinitis pigmentosa. The purpose of this study was to develop clinically-compatible methods for manufacturing photoreceptor precursor cells from adult skin in a non-profit cGMP environment. Biopsies were obtained ... More